Indeed, MEK inhibition robustly block naive CD8+ T cell, but truly increase the number of antigen‐specific CD8+ T cells within the tumor, and protect tumor‐infiltrating CD8+ T cells from apoptosis driven by chronic TCR stimulation while preserving their cytotoxic activity. The gene discussed is MAP2K7; the disease is neoplasm.